Loading…
for educational and safety purposes
Cariprazine and Risperidone both come up in the same conversations; they overlap on Dopamine and Serotonin. Cariprazine: Cariprazine, sold as Vraylar (and Reagila in Europe), is a third-generation antipsychotic. Risperidone: Risperidone is a second-generation (atypical) antipsychotic used for schizophrenia, bipolar mania and irritability in some conditions.
Cariprazine, sold as Vraylar (and Reagila in Europe), is a third-generation antipsychotic. Rather than simply blocking dopamine, it is a dopamine D3-preferring D2/D3 receptor partial agonist, meaning it partly activates those receptors and buffers dopamine signaling up or down toward a middle setpoint; it is also a 5-HT1A partial agonist and a 5-HT2B antagonist. It is used for schizophrenia and for bipolar disorder, including bipolar depression, and its standout feature is an unusually high affinity for the D3 receptor that is thought to help the negative and cognitive symptoms ordinary antipsychotics tend to leave untouched.
Risperidone is a second-generation (atypical) antipsychotic used for schizophrenia, bipolar mania and irritability in some conditions. Like other atypicals it blocks both dopamine D2 and serotonin 5-HT2A receptors, which broadens its effect and, at moderate doses, softens the movement side effects seen with older drugs. It is not recreational; it tends to feel sedating and flattening rather than pleasant.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Partial agonist
Antagonist
Antagonist
Partial agonist (high affinity, D3-preferring)
Partial agonist
Antagonist
Antagonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.